A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs GX 301 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Laboratoires Leurquin-Mediolanum
- 31 Aug 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 31 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 10 Jun 2017 Biomarkers information updated